Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias

Cabozantinib is an orally available, multi-target tyrosine kinase inhibitor approved for the treatment of several solid tumours and known to inhibit KIT tyrosine kinase. In acute myeloid leukaemia (AML), aberrant KIT tyrosine kinase often coexists with t(8;21) to drive leukaemogenesis. Here we evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Kuan-Wei, Ou, Da-Liang, Fu, Yu-Hsuan, Tien, Hwei-Fang, Hou, Hsin-An, Lin, Liang-In
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113930/
https://www.ncbi.nlm.nih.gov/pubmed/33833412
http://dx.doi.org/10.1038/s41417-021-00329-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113930/
https://www.ncbi.nlm.nih.gov/pubmed/33833412
http://dx.doi.org/10.1038/s41417-021-00329-1

Ejemplares similares